Hyperfine Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Hyperfine non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-1.3%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-1.3%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results

Nov 15

Hyperfine appoints Maria Sainz as President, CEO

Oct 06

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Aug 10

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di HYPR siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di HYPR siano aumentati.

Rendimento dei dividendi rispetto al mercato

Hyperfine Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di HYPR rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (HYPR)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.2%
Media del settore (Medical Equipment)	1.6%
Analista previsionale (HYPR) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di HYPR rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di HYPR rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di HYPR per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché HYPR non ha segnalato alcun pagamento.

Hyperfine Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results

Hyperfine, Inc. Updates Revenue Guidance for the Year 2024

Hyperfine, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients

Hyperfine, Inc. Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-In-Class Ultra-Low-Field Brain Images

Hyperfine, Inc. Highlights Positive Results from Multi-Site Observational Study on Swoop® System for Stroke Assessment

Hyperfine, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine, Inc. Provides Earnings Guidance for the Year 2024

Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024

Hyperfine, Inc., Annual General Meeting, Jun 11, 2024

Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System

Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Hyperfine, Inc. Announces Executive Changes

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System

Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up

Hyperfine, Inc. Announces Chief Financial Officer Changes

Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Hyperfine Names Maria Sainz as Chief Executive Officer, Effective October 24, 2022

Hyperfine appoints Maria Sainz as President, CEO

Consensus forecasts updated

Founder & Vice Chairman recently bought US$442k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Hyperfine, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Hyperfine, Inc. Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients

Hyperfine, Inc. Announces Executive Changes, Effective July 29, 2022

Hyperfine stock plunges 14% as CEO Dave Scott steps down

Founder & Vice Chairman recently bought US$119k worth of stock

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Hyperfine, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Hyperfine, Inc., Annual General Meeting, Jun 08, 2022

Hyperfine, Inc. to Report Q1, 2022 Results on May 11, 2022

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Hyperfine: MR Imaging In A Swoop

Hyperfine, Inc. to Report Q4, 2021 Results on Mar 23, 2022

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

Hyperfine, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Hyperfine, Inc. announced a financing transaction

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti